The European Commission said on Wednesday (March 24) that it had given €32 million to two tuberculosis (TB) initiatives aimed at developing new vaccines to fight the disease.

The commission made its announcement on World TB Day, saying the funding would bring together a collaborative effort that was the biggest of its kind, including 52 research teams from academia and industry from 15 European and African countries.

The cash will be used in two overlapping research projects. The TB-VAC project will develop vaccines that work in adults and are safe to use in poor health infrastructure settings. The second project, Mucosal Vaccines for Poverty Related Diseases (MUVAPRED), focuses on vaccine delivery by developing HIV and TB vaccines that can be taken orally or as a nasal spray.

“Despite today's potential in scientific knowledge and technology, poverty-related diseases such as tuberculosis are not eradicated yet. More than ever, the only...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?